Theme: Advancement in Prostate Cancer Research and Treatment

Prostate Cancer-2015

Renowned Speakers

Prostate Cancer-2015

OMICS International welcomes to the Prostate Cancer Congress during June22-24, 2015 at Florida USA. The theme of the conference is “Advancement in Prostate Cancer Research and Treatment ". Our aim is to aggregate researchers, academicians and scientists from the Prostate Cancer community and to create a platform for robust exchange of information on technological advances, new scientific achievements, and the effectiveness of various regulatory programs towards Prostate cancer.

OMICS International Organises 1000+ Global Events  Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 500  Open access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.Conference Series providing readers with the latest developments in Pharma, Medicine, Science and Technology presented at international conferences.

Prostate cancer occurs mainly in older men. About 6 cases in 10 are diagnosed in men aged 65 or older, and it is rare before age 40. The average age at the time of diagnosis is about 66. Compared to skin cancer, prostate cancer is the most common cancer in American men. It is the second most common cause of death from cancer among white, African American, American Indian and the fourth most common cause of death from cancer among Asian/Pacific Islander men.About 1 man in 36 will die of prostate cancer.

Death rates for prostate cancer have been  decreasing in many developed countries, including United States , Australia Canada, Finland, France, Israel, Italy, The Netherlands, Norway, Portugal, Sweden and  the United Kingdom.In contrast, mortality rates are rising in some Asian and Eastern European countries, such as Japan,Singapore, and Poland. While the decrease in prostate cancer death rates in Western European  and North American countries has been attributed mainly to improved treatment.Estimated deaths and new cases in United States in 2014 are about 29,480 men will die of prostate cancer and about 233,000 new cases of prostate cancer will be diagnosed.


Track 1 - Current and Future Perspectives on Prostate Cancer

Prostate Cancer International mortality rates vary widely across the world.Prostate cancer,also known as carcinoma of the prostate, is the development of cancer in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, some grow relatively fast. About 1 in 35 men will die from it.The accumulated scientific evidence concerning the associations between diet, lifestyle, and risk of prostate cancer development suggests that there are some identified modifiable risk factors that it might be recommended to change in order to decrease the risk for this common cancer site. About 75% of prostate cancers are considered sporadic, meaning that the genetic changes occur by chance after a person is born. Obesity and Overweightmay be associated with a very slight increase in the risk of prostate cancer. High cholesterol in the blood of men who underwent surgery for prostate cancer, were associated with increased risk for disease recurrence. Men, who have had certain previous cancers in the past, may have a slightly increased risk of getting prostate cancer. Prostate cancer medical treatmentoptions depend on several factors, such as how fast your cancer is growing, how much it has spread and your overall health, as well as the benefits and the potential side effects of the treatment. Vascular diseasewas significantly related to advance metastatic Prostate Cancer. Estimated deaths and new cases in United States in 2014 are about 29,480 men will die of prostate cancer and about 233,000 new cases of prostate cancer will be diagnosed.


Track 2 - Benign Prostatic Hyperplasia

Prostate Cancer Scientific Conference will offer an unforgettable experience to the scientific community through exclusive research presentations. Benign prostatic hyperplasia (BPH) involves enlargement of the prostate gland. Symptoms and causesinclude Urinary frequency, Urinary urgency, Hesitancy, Incomplete bladder emptying, Straining, Decreased force of stream, Dribbling . Tests and diagnosisof BPH include Digital rectal exam, Urine test, Epidemiology Medication and Treatment Lifestyle management. Prostatic acid phosphatase (PAP), also prostatic specific acid phosphatase (PSAP), is an enzyme produced by the prostate. In the human male reproductive system, retrograde ejaculation occurs when semen, which would normally be ejaculated via the urethra, is redirected to the urinary bladder. Proliferative inflammatory atrophy (PIA) belongs to the atrophic lesions that frequently occur in the prostate. Dihydrotestosterone  (5α-Dihydrotestosterone), is a male sex hormone, an androgen. 5α-reductase, an enzyme, synthesizes DHT in the adrenal glands, hair follicles, testes and prostate.


Track 3 - Treatments for Castration Resistant Prostate Cancer

Prostate cancer conference  include scientific keynote lectures, sympoisa, workshops, exhibitions.Treatment option for Prostate Cancer include Active Surveillance , Prostatectomy (Surgery) , Radiation Therapy , Hormone Therapy , Chemotherapy and Other castration resistant prostate treatment Options. The concept of active surveillance, or watchful waiting, has increasingly emerged in recent years as a viable option for men who decide not to undergo immediate surgery or radiation therapy. Prostatectomy is a medical term for the surgical removal of all or part of the prostate gland. Radiation therapy uses high-energy rays or particles to kill cancer cells. Hormone therapy is also called androgen deprivation therapy (ADT) or androgen suppression therapy. The goal is to reduce levels of male hormones, called androgens, in the body, or to stop them from affecting prostate cancer cells. Chemotherapy (chemo) uses anti-cancer drugs injected into a vein or given by mouth. These drugs enter the bloodstream and go throughout the body, making this treatment potentially useful for cancers that have spread (metastasized) to distant organs. Immunotherapy works by either stimulating your immune system to attack cancer cells or providing your immune system with what it needs, such as antibodies, to fight cancer. Prostatic intraepithelial neoplasia (PIN) is a condition in which some of the prostate's epithelial cells look abnormal under the microscope. Zytiga has quickly become the treatment of choice for docetaxel-pretreated metatastatic castrate-resistant prostate cancer (mCRPC) patients, says the study. By 2015, less than two years after its launch, the drug is expected to garner major-market peak-year sales of $1.8 billion, it adds.


Track 4 - Translational Research and Pathology

Prostate Cancer 2015 brings together world leaders presenting their expertise and current research on all areas of prostate cancer. Gene profiling and expression analysis using microarrays have made a significant impact on our biological understanding of prostate cancer. A prostate biopsy is a procedure to remove samples of suspicious tissue from the prostate. Biomarker tests continue to impact the world of prostate cancer from early detection through diagnosis, by helping men to better understand their risk of having the disease and identifying the aggressiveness of the disease if present. A combination of 2 urine-based genetic biomarkers predicts prostate cancer better than either biomarker alone and better than the standard serum prostate-specific antigen (PSA). The use of epigenetic testing for prostate cancer detection using methylation specific PCR (MSP) and cancer-associated epigenetic biomarkers to improve upon histopathology has been well validated in both scientific and clinical studies. Prostatodynia is a type of inflammation of the prostate not due to bacterial infection and in which there are no objective findings, such as the presence of infection-fighting cells, in the urine of men who suffer from the disease. About 6 cases in 10 are diagnosed in men aged 65 or older, and it is rare before age 40.


Track 5 - Screening and early diagnosis of prostate cancer

Prostate cancer conference Florida welcomes all the researchers and eminent personalities in the field of Prostate Cancer. Tests commonly used to screen for prostate cancer include PSA screening - Prostate specific antigen (PSA) test measures the level of PSA in the blood. PSA is a substance made by the prostate. The levels of PSA in the blood can be higher in men who have prostate cancer. The main type of surgery for prostate cancer is known as a radical prostatectomy. In this operation, the surgeon removes the entire prostate gland plus some of the tissue around it, including the seminal vesicles. Clinical case discussions on prostate cancer include Case Reports on Prostate Cancer, Case Study: Castrate-Resistant Prostate Cancer. Proton therapy for prostate cancer is a treatment option that involves using a focused ray of proton particles to destroy cancerous tissues. The Prostascint scan was developed in order to help doctors detect the spread of prostate cancer to other parts of the body, particularly the lymph nodes.The diagnosis and screening segment is expected to total $12.1 billion in 2012 and $17.4 billion in2017, a CAGR of 7.5%.


Track 6 - Prostatitis

The Prostate Cancer World Congress 2015 is the world’s largest multidisciplinary prostate cancer meeting.Prostatitis is a frequently painful condition that involves inflammation of the prostate and sometimes the areas around the prostate. Types of Prostatitis include Acute bacterial prostatitis (ABP), Chronic bacterial prostatitis (CBP), Nonbacterial prostatitis and Prostatodynia .Causes and Symptoms of Prostatitis include: Causes-Engage in rectal intercourse, Have an abnormal urinary tract. Have had a recent bladder infection, Have an enlarged prostate and Symptoms-Frequent urge to urinate, Difficulty urinating, Pain or burning during urination, chills and fever. The treatment for prostatitis depends on the underlying cause and type of prostatitis. Treatment modalities may include the following: Antibiotics, Anti-inflammatory medications , Alpha-blockers , Lifestyle changes and Acupuncture. Prevention of prostatitis include Practice good hygiene, and keep your penis clean , Drink enough fluids to cause regular urination , Seek early treatment of a possible urinary tract infection. Epididymitis is a medical condition characterized by discomfort or pain of the epididymis, a curved structure at the back of the testicle in which sperm matures and is stored.


Track 7 - Radical Prostatectomy

A radical prostatectomy is an operation to remove the prostate gland camera.gif and some of the tissue around it. It is done to remove prostate cancer. This operation may be done by open surgery or it may be done by laparoscopic surgery. In open surgery, the surgeon makes an incision to reach the prostate gland. Depending on the case, the incision is made either in the lower belly or in the perineum between the anus and the scrotum. For laparoscopic surgery, the surgeon makes several small incisions in the belly. Robotic-assisted laparoscopic radical prostatectomy is surgery done through small incisions in the belly with robotic arms that translate the surgeon's hand motions into finer and more precise action. Risks after surgery are Problems controlling bowel movements, Problems controlling urine, Erection problems, Injury to the rectum, Urethral stricture. As a segment, surgical and radiation therapy should total $9 billion in 2012 and nearly $14.3 billion in 2017, a CAGR of 9.7%.A prosthesis is a device designed to replace a missing part of the body or to make a part of the body work better. Transurethral resection of the prostate (TURP) is a type of prostate surgery done to relieve moderate to severe urinary symptoms caused by an enlarged prostate.The Global Congress on Prostate Cancer 2015 aims to bring together top experts and delegates for an in-depth discussion of the different aspects of prostate cancer


Track 8 - PCa Oncology and Clinical Trials on Prostate Cancer

Clinical scientists and laboratory investigators study the basic biology of prostate cancer to hunt for even better ways to detect it and treat it. Clinical trials for metastatic prostate cancer and Clinical trials for advanced prostate cancer play a crucial role in moving new treatments to patients who need them most, securing data so regulatory approvals can be obtained and new drugs can move into widespread clinical practiceNew treatments on prostate cancer include Surgery, Radiation, Hormone therapy, Chemo therapy, Biologic therapy and Bisphosphonate therapy. Unlike vaccines against infections like measles or mumps, prostate cancer vaccines are designed to help treat, not prevent, prostate cancer. One possible advantage of these types of treatments is that they seem to have very limited side effects. Drug therapeutics are expected to reach $8.1 billion in 2012 and nearly $18.6 billion in 2017, a CAGR of 18%.


Track 9 - Prostate Cancer Side Effects and Management

Prostate Cancer Side Effects include Bladder inflammation where you may find that you have to pass urine more often than usual. And you may have a burning feeling when you do. This is called radiation cystitis. Urinary dysfunction encompasses both urinary incontinence, which can range from some leaking to complete loss of bladder control, and irritative voiding symptoms, including increased urinary frequency, increased urinary urgency, and pain upon urination. Bowel dysfunction includes diarrhea or frequent stools; fecal incontinence or the inability to control bowel movements; and rectal bleeding. Most treatments for prostate cancer cause infertility or loss of fertility. Several techniques can help preserve fertility, but they must be done before cancer treatment. The side effects of chemotherapy depend on the type and dose of drugs given and the length of time they are taken. Side effects may include Hair loss, Mouth sores, Loss of appetite, Nausea and vomiting, Diarrhea. Possible side effects of hormone therapy include Reduced or absent libido (sexual desire), Impotence (erectile dysfunction), Shrinkage of testicles and penis, Osteoporosis (bone thinning), which can lead to broken bones. The global market for the prevention and treatment of prostate cancer was valued at $26.1 billion in 2011 and should reach nearly $29.3 billion in 2012. Total market value is expected to reach $50.3 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 11.4%.


Track 10 - State-of-the art: vision on the future

Current state of the art, multimodality research and future visions for the treatment of patients with prostate cancer: consensus results from “Challenges and Chances in Prostate Cancer Research .A urologist, a radiation oncologist, and a medical oncologist—will give you the most comprehensive assessment of the available treatments and expected outcomes. Nuclear scans make pictures based on the body’s chemistry rather than on physical shapes and forms PET/CT scanners give information on any areas of increased cell activity. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. Taken together, the prostate biopsy scenario is currently becoming distinctively complex. It has clearly moved far beyond any prostate cancer detection, or avoiding biopsy-related complications such as infections or patients’ anxiety. Importantly, the future of prostate imaging especially of multiparametric MRI-based technology has already begun. Target audience include medical oncologists, radiation oncologists, surgeons, and urologists involved in the treatment and management of patients with prostate cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals interested in the treatment of prostate cancer.Prostate Cancer 2016 event brought together world leaders in prostate cancer, to share their knowledge and experience in all facets of management and treatment.


Dear Prostate Cancer Researchers and Clinicians

I would like to welcome you to Prostate Cancer 2015 in the beautiful and exciting city of Orlando, Florida. This meeting will be full of exciting presentations by top prostate cancer experts around the world. It will be a great venue to present and discuss new and exciting preclinical and clinical findings with your colleagues coming from cancer centers all over the world. This will also be a nice opportunity for doctors in training who are interested in a career in prostate cancer treatment and research. There will be ample opportunity to meet with experts and have informal discussions in addition to various sessions of the meeting. In addition to plenary and oral abstract presentation sessions, there will be poster sessions giving you plenty of opportunity to interact with colleagues, students, trainees and experienced researchers and clinicians.

I look forward to seeing you at this exciting meeting in a beautiful setting!

Warm regards,
Omer Kucuk
Emory University School of Medicine



To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date June 22-24, 2015
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Closed Day 1 Day 2 Day 3
Poster Opportunity Closed Click Here to View